DISINFO: Russia invented a cure for coronavirus
  • Outlet: cz.sputniknews.com (archived)*
  • Date of publication: March 28, 2020
  • Outlet language(s): Czech
  • Reported in: Issue 191
  • Countries / regions discussed: Russia

DISINFO: Russia invented a cure for coronavirus


Russia introduced a drug for the treatment of a new type of coronavirus. The drug is based on the antimalarial drug mefloquine and is also developing an effective and safe system of prevention against coronavirus.


This is part of the pro-Kremlin disinformation campaign around the coronavirus. According to WHO, to date, there is no specific medicine recommended to prevent or treat the new coronavirus (2019-nCoV). The anti-malarial drug mefloquine has been considered as a drug against a new type of coronavirus in several countries. The tests were carried out, for example, by China or France. However, its efficacy has not been verified and extensive clinical trials would have to be carried out for general use. A French medicine watchdog ANSM even has warned of the dangerous side effects of malaria drugs being used against the novel coronavirus due to some crucial side effects that appeared at several patients who used them for self-medication.


Related disinfo cases


Cases in the EUvsDisinfo database focus on messages in the international information space that are identified as providing a partial, distorted, or false depiction of reality and spread key pro-Kremlin messages. This does not necessarily imply, however, that a given outlet is linked to the Kremlin or editorially pro-Kremlin, or that it has intentionally sought to disinform. EUvsDisinfo publications do not represent an official EU position, as the information and opinions expressed are based on media reporting and analysis of the East Stratcom Task Force.

    Your opinion matters!

    Data Protection Information *

      Subscribe to the Disinfo Review

      Your weekly update on pro-Kremlin disinformation

      Data Protection Information *

      The Disinformation Review is sent through Mailchimp.com. See Mailchimp’s privacy policy and find out more on how EEAS protects your personal data.